# OnCo record mestag-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/mestag-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "mestag-therapeutics" ;
  schema:name "Mestag Therapeutics"@en ;
  schema:alternateName "Mestag Therapeutics Limited"@en ;
  schema:description "Mestag Therapeutics, in Cambridge in the UK, makes antibodies that act on fibroblasts, the support cells around a tumour, to help the immune system organise an attack inside the tumour. Its first medicine, MST-0312, is in an early trial in advanced solid tumours."@en ;
  schema:url <https://onco.cc/companies/mestag-therapeutics/>, <https://www.mestagtherapeutics.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://www.mestagtherapeutics.com/>, <https://www.mestagtherapeutics.com/2026/03/17/mestag-therapeutics-announces-40-million-financing-and-appoints-chief-medical-officer-and-chief-development-officer-in-preparation-to-enter-the-clinic/>, <https://www.mestagtherapeutics.com/2026/05/19/mestag-therapeutics-announces-the-first-patient-dosed-with-mst-0312-in-the-phase-i-starlys-trial/>, <https://clinicaltrials.gov/study/NCT07610941> ;
  schema:addressCountry "GB" ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/bispecific-antibody/> ;
  onco:targets <https://onco.cc/targets/fap/> .